Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.
Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego Health System, San Diego, Calif.
J Vasc Surg. 2020 Nov;72(5):1701-1710. doi: 10.1016/j.jvs.2020.02.036. Epub 2020 Apr 3.
Recent data have shown that transcarotid artery revascularization (TCAR) with flow reversal provides a superior method of embolic protection compared with transfemoral carotid artery stenting (tfCAS) with distal embolic protection. Flow reversal or flow arrest systems with proximal endovascular balloon occlusion can also be used through the transfemoral approach; however, their outcomes compared with TCAR with flow reversal and tfCAS with distal embolic protection are poorly described.
We performed a retrospective review of all patients undergoing tfCAS with proximal balloon occlusion, tfCAS with distal embolic protection, and TCAR with flow reversal in the Society for Vascular Surgery Vascular Quality Initiative from March 2005 to May 2019. We assessed in-hospital outcomes in propensity score-matched cohorts of patients using tfCAS with proximal balloon occlusion as the comparison cohort. The primary outcome was stroke or death. Secondary end points included the individual outcomes of stroke, death, transient ischemic attack (TIA), and myocardial infarction.
Of the 24,232 patients undergoing carotid artery stenting, 561 (2.3%) procedures were performed through tfCAS with proximal balloon occlusion, 18,126 (74%) through tfCAS with distal embolic protection, and 5545 (22.9%) through TCAR with flow reversal. After matching, 463 pairs of patients undergoing tfCAS with proximal balloon occlusion and tfCAS with distal embolic protection were identified. There were no differences in stroke or death (proximal balloon, 3.2%; distal embolic protection, 3.7%; relative risk [RR], 0.88; 95% confidence interval [CI], 0.45-1.73; P = .73), stroke (2.4% vs 2.6%; RR, 0.92; 95% CI, 0.42-2.00; P = .83), death (1.1% vs 1.5%; RR, 0.71; 95% CI, 0.41-3.15; P = .80), TIA (1.7% vs 1.5%; RR, 1.14; 95% CI, 0.41-3.15; P = .80), or myocardial infarction (0.4% vs 0.6%; RR, 0.67; 95% CI, 0.11-3.99; P = .65). However, after matching 357 pairs of patients undergoing tfCAS with proximal balloon occlusion and TCAR with flow reversal, tfCAS with proximal balloon occlusion was associated with higher rates of stroke or death (3.1% vs 0.8%; RR, 3.67; 95% CI, 1.02-13.14; P = .03) and a trend toward higher rates of stroke (2.5% vs 0.8%; RR, 3.00; 95% CI, 0.81-11.08; P = .08) and death (0.8% vs 0.0%; P = .08), but no statistically significant differences in TIA (0.8% vs 0.8%; P > .99) or myocardial infarction (0.6% vs 0.3%; RR, 2.00; 95% CI, 0.18-22.06; P = .56).
Compared with tfCAS with distal embolic protection, tfCAS with proximal balloon occlusion has similar major outcomes. However, tfCAS with proximal balloon occlusion does not offer the same degree of embolic protection compared with TCAR with flow reversal, given the significantly higher risk of perioperative stroke or death.
最近的数据表明,与经股动脉颈动脉支架置入术(tfCAS)联合远端栓塞保护相比,经颈动脉动脉血运重建(TCAR)联合血流反转提供了一种更好的栓塞保护方法。通过经股动脉途径也可以使用近端血管内球囊闭塞的血流反转或血流阻断系统;然而,与 TCAR 联合血流反转和 tfCAS 联合远端栓塞保护相比,其结果描述较差。
我们对 2005 年 3 月至 2019 年 5 月期间血管外科学会血管质量倡议(Society for Vascular Surgery Vascular Quality Initiative)中所有接受 tfCAS 近端球囊闭塞、tfCAS 远端栓塞保护和 TCAR 血流反转治疗的患者进行了回顾性分析。我们使用 tfCAS 近端球囊闭塞作为比较队列,在倾向评分匹配的患者队列中评估了住院期间的结果。主要结局是卒中或死亡。次要终点包括卒中、死亡、短暂性脑缺血发作(TIA)和心肌梗死的单独结局。
在 24232 例颈动脉支架置入术患者中,561 例(2.3%)采用 tfCAS 近端球囊闭塞治疗,18126 例(74%)采用 tfCAS 远端栓塞保护治疗,5545 例(22.9%)采用 TCAR 血流反转治疗。匹配后,我们确定了 463 对接受 tfCAS 近端球囊闭塞和 tfCAS 远端栓塞保护的患者。卒中或死亡无差异(近端球囊闭塞组 3.2%;远端栓塞保护组 3.7%;相对风险[RR],0.88;95%置信区间[CI],0.45-1.73;P=.73)、卒中(2.4% vs 2.6%;RR,0.92;95%CI,0.42-2.00;P=.83)、死亡(1.1% vs 1.5%;RR,0.71;95%CI,0.41-3.15;P=.80)、TIA(1.7% vs 1.5%;RR,1.14;95%CI,0.41-3.15;P=.80)或心肌梗死(0.4% vs 0.6%;RR,0.67;95%CI,0.11-3.99;P=.65)。然而,在匹配 357 对接受 tfCAS 近端球囊闭塞和 TCAR 血流反转的患者后,tfCAS 近端球囊闭塞与更高的卒中或死亡发生率(3.1% vs 0.8%;RR,3.67;95%CI,1.02-13.14;P=.03)和更高的卒中发生率(2.5% vs 0.8%;RR,3.00;95%CI,0.81-11.08;P=.08)和死亡(0.8% vs 0.0%;P=.08)的趋势相关,但 TIA(0.8% vs 0.8%;P >.99)或心肌梗死(0.6% vs 0.3%;RR,2.00;95%CI,0.18-22.06;P=.56)发生率无统计学差异。
与 tfCAS 远端栓塞保护相比,tfCAS 近端球囊闭塞具有相似的主要结局。然而,与 TCAR 血流反转相比,tfCAS 近端球囊闭塞并不能提供相同程度的栓塞保护,因为围手术期卒中或死亡的风险明显更高。